1 Study Coverage
    1.1 Recombinant Plasma Protein Therapeutics Product Introduction
    1.2 Market by Type
        1.2.1 Global Recombinant Plasma Protein Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Recombinant Coagulation Factors
        1.2.3 Human C1 Esterase Inhibitor
    1.3 Market by Application
        1.3.1 Global Recombinant Plasma Protein Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hemophilia A
        1.3.3 Hemophilia B
        1.3.4 Von Willebrand Disease
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Recombinant Plasma Protein Therapeutics Sales Estimates and Forecasts 2017-2028
    2.2 Global Recombinant Plasma Protein Therapeutics Revenue Estimates and Forecasts 2017-2028
    2.3 Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Recombinant Plasma Protein Therapeutics Sales by Region
        2.4.1 Global Recombinant Plasma Protein Therapeutics Sales by Region (2017-2022)
        2.4.2 Global Sales Recombinant Plasma Protein Therapeutics by Region (2023-2028)
    2.5 Global Recombinant Plasma Protein Therapeutics Revenue by Region
        2.5.1 Global Recombinant Plasma Protein Therapeutics Revenue by Region (2017-2022)
        2.5.2 Global Recombinant Plasma Protein Therapeutics Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Recombinant Plasma Protein Therapeutics Sales by Manufacturers
        3.1.1 Global Top Recombinant Plasma Protein Therapeutics Manufacturers by Sales (2017-2022)
        3.1.2 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Plasma Protein Therapeutics in 2021
    3.2 Global Recombinant Plasma Protein Therapeutics Revenue by Manufacturers
        3.2.1 Global Recombinant Plasma Protein Therapeutics Revenue by Manufacturers (2017-2022)
        3.2.2 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Recombinant Plasma Protein Therapeutics Revenue in 2021
    3.3 Global Recombinant Plasma Protein Therapeutics Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Recombinant Plasma Protein Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Recombinant Plasma Protein Therapeutics Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Recombinant Plasma Protein Therapeutics Sales by Type
        4.1.1 Global Recombinant Plasma Protein Therapeutics Historical Sales by Type (2017-2022)
        4.1.2 Global Recombinant Plasma Protein Therapeutics Forecasted Sales by Type (2023-2028)
        4.1.3 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2017-2028)
    4.2 Global Recombinant Plasma Protein Therapeutics Revenue by Type
        4.2.1 Global Recombinant Plasma Protein Therapeutics Historical Revenue by Type (2017-2022)
        4.2.2 Global Recombinant Plasma Protein Therapeutics Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2017-2028)
    4.3 Global Recombinant Plasma Protein Therapeutics Price by Type
        4.3.1 Global Recombinant Plasma Protein Therapeutics Price by Type (2017-2022)
        4.3.2 Global Recombinant Plasma Protein Therapeutics Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Recombinant Plasma Protein Therapeutics Sales by Application
        5.1.1 Global Recombinant Plasma Protein Therapeutics Historical Sales by Application (2017-2022)
        5.1.2 Global Recombinant Plasma Protein Therapeutics Forecasted Sales by Application (2023-2028)
        5.1.3 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2017-2028)
    5.2 Global Recombinant Plasma Protein Therapeutics Revenue by Application
        5.2.1 Global Recombinant Plasma Protein Therapeutics Historical Revenue by Application (2017-2022)
        5.2.2 Global Recombinant Plasma Protein Therapeutics Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2017-2028)
    5.3 Global Recombinant Plasma Protein Therapeutics Price by Application
        5.3.1 Global Recombinant Plasma Protein Therapeutics Price by Application (2017-2022)
        5.3.2 Global Recombinant Plasma Protein Therapeutics Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Recombinant Plasma Protein Therapeutics Market Size by Type
        6.1.1 North America Recombinant Plasma Protein Therapeutics Sales by Type (2017-2028)
        6.1.2 North America Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2028)
    6.2 North America Recombinant Plasma Protein Therapeutics Market Size by Application
        6.2.1 North America Recombinant Plasma Protein Therapeutics Sales by Application (2017-2028)
        6.2.2 North America Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2028)
    6.3 North America Recombinant Plasma Protein Therapeutics Market Size by Country
        6.3.1 North America Recombinant Plasma Protein Therapeutics Sales by Country (2017-2028)
        6.3.2 North America Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Recombinant Plasma Protein Therapeutics Market Size by Type
        7.1.1 Europe Recombinant Plasma Protein Therapeutics Sales by Type (2017-2028)
        7.1.2 Europe Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2028)
    7.2 Europe Recombinant Plasma Protein Therapeutics Market Size by Application
        7.2.1 Europe Recombinant Plasma Protein Therapeutics Sales by Application (2017-2028)
        7.2.2 Europe Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2028)
    7.3 Europe Recombinant Plasma Protein Therapeutics Market Size by Country
        7.3.1 Europe Recombinant Plasma Protein Therapeutics Sales by Country (2017-2028)
        7.3.2 Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Recombinant Plasma Protein Therapeutics Market Size by Type
        8.1.1 Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2017-2028)
        8.1.2 Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2028)
    8.2 Asia Pacific Recombinant Plasma Protein Therapeutics Market Size by Application
        8.2.1 Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2017-2028)
        8.2.2 Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2028)
    8.3 Asia Pacific Recombinant Plasma Protein Therapeutics Market Size by Region
        8.3.1 Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Region (2017-2028)
        8.3.2 Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Recombinant Plasma Protein Therapeutics Market Size by Type
        9.1.1 Latin America Recombinant Plasma Protein Therapeutics Sales by Type (2017-2028)
        9.1.2 Latin America Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2028)
    9.2 Latin America Recombinant Plasma Protein Therapeutics Market Size by Application
        9.2.1 Latin America Recombinant Plasma Protein Therapeutics Sales by Application (2017-2028)
        9.2.2 Latin America Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2028)
    9.3 Latin America Recombinant Plasma Protein Therapeutics Market Size by Country
        9.3.1 Latin America Recombinant Plasma Protein Therapeutics Sales by Country (2017-2028)
        9.3.2 Latin America Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Type
        10.1.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2028)
    10.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Application
        10.2.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2028)
    10.3 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Country
        10.3.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 CSL Limited
        11.1.1 CSL Limited Corporation Information
        11.1.2 CSL Limited Overview
        11.1.3 CSL Limited Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 CSL Limited Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 CSL Limited Recent Developments
    11.2 Takeda
        11.2.1 Takeda Corporation Information
        11.2.2 Takeda Overview
        11.2.3 Takeda Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Takeda Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Takeda Recent Developments
    11.3 Octapharma
        11.3.1 Octapharma Corporation Information
        11.3.2 Octapharma Overview
        11.3.3 Octapharma Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Octapharma Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Octapharma Recent Developments
    11.4 Novo Nordisk A/S
        11.4.1 Novo Nordisk A/S Corporation Information
        11.4.2 Novo Nordisk A/S Overview
        11.4.3 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Novo Nordisk A/S Recent Developments
    11.5 Pfizer
        11.5.1 Pfizer Corporation Information
        11.5.2 Pfizer Overview
        11.5.3 Pfizer Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Pfizer Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Pfizer Recent Developments
    11.6 Bioverativ Therapeutics
        11.6.1 Bioverativ Therapeutics Corporation Information
        11.6.2 Bioverativ Therapeutics Overview
        11.6.3 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Bioverativ Therapeutics Recent Developments
    11.7 Aptevo Therapeutics
        11.7.1 Aptevo Therapeutics Corporation Information
        11.7.2 Aptevo Therapeutics Overview
        11.7.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Aptevo Therapeutics Recent Developments
    11.8 Pharming Group
        11.8.1 Pharming Group Corporation Information
        11.8.2 Pharming Group Overview
        11.8.3 Pharming Group Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Pharming Group Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Pharming Group Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Recombinant Plasma Protein Therapeutics Industry Chain Analysis
    12.2 Recombinant Plasma Protein Therapeutics Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Recombinant Plasma Protein Therapeutics Production Mode & Process
    12.4 Recombinant Plasma Protein Therapeutics Sales and Marketing
        12.4.1 Recombinant Plasma Protein Therapeutics Sales Channels
        12.4.2 Recombinant Plasma Protein Therapeutics Distributors
    12.5 Recombinant Plasma Protein Therapeutics Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Recombinant Plasma Protein Therapeutics Industry Trends
    13.2 Recombinant Plasma Protein Therapeutics Market Drivers
    13.3 Recombinant Plasma Protein Therapeutics Market Challenges
    13.4 Recombinant Plasma Protein Therapeutics Market Restraints
14 Key Findings in The Global Recombinant Plasma Protein Therapeutics Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Recombinant Plasma Protein Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Recombinant Coagulation Factors
    Table 3. Major Manufacturers of Human C1 Esterase Inhibitor
    Table 4. Global Recombinant Plasma Protein Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 5. Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Recombinant Plasma Protein Therapeutics Sales by Region (2017-2022) & (K Units)
    Table 7. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Region (2017-2022)
    Table 8. Global Recombinant Plasma Protein Therapeutics Sales by Region (2023-2028) & (K Units)
    Table 9. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Region (2023-2028)
    Table 10. Global Recombinant Plasma Protein Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 11. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Region (2017-2022)
    Table 12. Global Recombinant Plasma Protein Therapeutics Revenue by Region (2023-2028) & (US$ Million)
    Table 13. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Region (2023-2028)
    Table 14. Global Recombinant Plasma Protein Therapeutics Sales by Manufacturers (2017-2022) & (K Units)
    Table 15. Global Recombinant Plasma Protein Therapeutics Sales Share by Manufacturers (2017-2022)
    Table 16. Global Recombinant Plasma Protein Therapeutics Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 17. Global Recombinant Plasma Protein Therapeutics Revenue Share by Manufacturers (2017-2022)
    Table 18. Recombinant Plasma Protein Therapeutics Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 19. Global Recombinant Plasma Protein Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global Recombinant Plasma Protein Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Plasma Protein Therapeutics as of 2021)
    Table 21. Recombinant Plasma Protein Therapeutics Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers Recombinant Plasma Protein Therapeutics Product Offered
    Table 23. Date of Manufacturers Enter into Recombinant Plasma Protein Therapeutics Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Recombinant Plasma Protein Therapeutics Sales by Type (2017-2022) & (K Units)
    Table 26. Global Recombinant Plasma Protein Therapeutics Sales by Type (2023-2028) & (K Units)
    Table 27. Global Recombinant Plasma Protein Therapeutics Sales Share by Type (2017-2022)
    Table 28. Global Recombinant Plasma Protein Therapeutics Sales Share by Type (2023-2028)
    Table 29. Global Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 30. Global Recombinant Plasma Protein Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 31. Global Recombinant Plasma Protein Therapeutics Revenue Share by Type (2017-2022)
    Table 32. Global Recombinant Plasma Protein Therapeutics Revenue Share by Type (2023-2028)
    Table 33. Recombinant Plasma Protein Therapeutics Price by Type (2017-2022) & (USD/Unit)
    Table 34. Global Recombinant Plasma Protein Therapeutics Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 35. Global Recombinant Plasma Protein Therapeutics Sales by Application (2017-2022) & (K Units)
    Table 36. Global Recombinant Plasma Protein Therapeutics Sales by Application (2023-2028) & (K Units)
    Table 37. Global Recombinant Plasma Protein Therapeutics Sales Share by Application (2017-2022)
    Table 38. Global Recombinant Plasma Protein Therapeutics Sales Share by Application (2023-2028)
    Table 39. Global Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 40. Global Recombinant Plasma Protein Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 41. Global Recombinant Plasma Protein Therapeutics Revenue Share by Application (2017-2022)
    Table 42. Global Recombinant Plasma Protein Therapeutics Revenue Share by Application (2023-2028)
    Table 43. Recombinant Plasma Protein Therapeutics Price by Application (2017-2022) & (USD/Unit)
    Table 44. Global Recombinant Plasma Protein Therapeutics Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 45. North America Recombinant Plasma Protein Therapeutics Sales by Type (2017-2022) & (K Units)
    Table 46. North America Recombinant Plasma Protein Therapeutics Sales by Type (2023-2028) & (K Units)
    Table 47. North America Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 48. North America Recombinant Plasma Protein Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 49. North America Recombinant Plasma Protein Therapeutics Sales by Application (2017-2022) & (K Units)
    Table 50. North America Recombinant Plasma Protein Therapeutics Sales by Application (2023-2028) & (K Units)
    Table 51. North America Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 52. North America Recombinant Plasma Protein Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 53. North America Recombinant Plasma Protein Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 54. North America Recombinant Plasma Protein Therapeutics Sales by Country (2023-2028) & (K Units)
    Table 55. North America Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 56. North America Recombinant Plasma Protein Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 57. Europe Recombinant Plasma Protein Therapeutics Sales by Type (2017-2022) & (K Units)
    Table 58. Europe Recombinant Plasma Protein Therapeutics Sales by Type (2023-2028) & (K Units)
    Table 59. Europe Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 60. Europe Recombinant Plasma Protein Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 61. Europe Recombinant Plasma Protein Therapeutics Sales by Application (2017-2022) & (K Units)
    Table 62. Europe Recombinant Plasma Protein Therapeutics Sales by Application (2023-2028) & (K Units)
    Table 63. Europe Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 64. Europe Recombinant Plasma Protein Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 65. Europe Recombinant Plasma Protein Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 66. Europe Recombinant Plasma Protein Therapeutics Sales by Country (2023-2028) & (K Units)
    Table 67. Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 68. Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 69. Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2017-2022) & (K Units)
    Table 70. Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2023-2028) & (K Units)
    Table 71. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 72. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2017-2022) & (K Units)
    Table 74. Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2023-2028) & (K Units)
    Table 75. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Region (2017-2022) & (K Units)
    Table 78. Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Region (2023-2028) & (K Units)
    Table 79. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Region (2023-2028) & (US$ Million)
    Table 81. Latin America Recombinant Plasma Protein Therapeutics Sales by Type (2017-2022) & (K Units)
    Table 82. Latin America Recombinant Plasma Protein Therapeutics Sales by Type (2023-2028) & (K Units)
    Table 83. Latin America Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 84. Latin America Recombinant Plasma Protein Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 85. Latin America Recombinant Plasma Protein Therapeutics Sales by Application (2017-2022) & (K Units)
    Table 86. Latin America Recombinant Plasma Protein Therapeutics Sales by Application (2023-2028) & (K Units)
    Table 87. Latin America Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 88. Latin America Recombinant Plasma Protein Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 89. Latin America Recombinant Plasma Protein Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 90. Latin America Recombinant Plasma Protein Therapeutics Sales by Country (2023-2028) & (K Units)
    Table 91. Latin America Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 92. Latin America Recombinant Plasma Protein Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 93. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Type (2017-2022) & (K Units)
    Table 94. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Type (2023-2028) & (K Units)
    Table 95. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 96. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Application (2017-2022) & (K Units)
    Table 98. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Application (2023-2028) & (K Units)
    Table 99. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 102. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2023-2028) & (K Units)
    Table 103. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 105. CSL Limited Corporation Information
    Table 106. CSL Limited Description and Major Businesses
    Table 107. CSL Limited Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 108. CSL Limited Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 109. CSL Limited Recent Developments
    Table 110. Takeda Corporation Information
    Table 111. Takeda Description and Major Businesses
    Table 112. Takeda Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 113. Takeda Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Takeda Recent Developments
    Table 115. Octapharma Corporation Information
    Table 116. Octapharma Description and Major Businesses
    Table 117. Octapharma Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 118. Octapharma Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Octapharma Recent Developments
    Table 120. Novo Nordisk A/S Corporation Information
    Table 121. Novo Nordisk A/S Description and Major Businesses
    Table 122. Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 123. Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Novo Nordisk A/S Recent Developments
    Table 125. Pfizer Corporation Information
    Table 126. Pfizer Description and Major Businesses
    Table 127. Pfizer Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 128. Pfizer Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Pfizer Recent Developments
    Table 130. Bioverativ Therapeutics Corporation Information
    Table 131. Bioverativ Therapeutics Description and Major Businesses
    Table 132. Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 133. Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Bioverativ Therapeutics Recent Developments
    Table 135. Aptevo Therapeutics Corporation Information
    Table 136. Aptevo Therapeutics Description and Major Businesses
    Table 137. Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 138. Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Aptevo Therapeutics Recent Developments
    Table 140. Pharming Group Corporation Information
    Table 141. Pharming Group Description and Major Businesses
    Table 142. Pharming Group Recombinant Plasma Protein Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 143. Pharming Group Recombinant Plasma Protein Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Pharming Group Recent Developments
    Table 145. Key Raw Materials Lists
    Table 146. Raw Materials Key Suppliers Lists
    Table 147. Recombinant Plasma Protein Therapeutics Distributors List
    Table 148. Recombinant Plasma Protein Therapeutics Customers List
    Table 149. Recombinant Plasma Protein Therapeutics Market Trends
    Table 150. Recombinant Plasma Protein Therapeutics Market Drivers
    Table 151. Recombinant Plasma Protein Therapeutics Market Challenges
    Table 152. Recombinant Plasma Protein Therapeutics Market Restraints
    Table 153. Research Programs/Design for This Report
    Table 154. Key Data Information from Secondary Sources
    Table 155. Key Data Information from Primary Sources
List of Figures
    Figure 1. Recombinant Plasma Protein Therapeutics Product Picture
    Figure 3. Global Recombinant Plasma Protein Therapeutics Market Share by Type in 2021 & 2028
    Figure 3. Recombinant Coagulation Factors Product Picture
    Figure 4. Human C1 Esterase Inhibitor Product Picture
    Figure 5. Global Recombinant Plasma Protein Therapeutics Market Share by Application in 2021 & 2028
    Figure 6. Hemophilia A
    Figure 7. Hemophilia B
    Figure 8. Von Willebrand Disease
    Figure 9. Recombinant Plasma Protein Therapeutics Report Years Considered
    Figure 10. Global Recombinant Plasma Protein Therapeutics Sales 2017-2028 (K Units)
    Figure 11. Global Recombinant Plasma Protein Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Recombinant Plasma Protein Therapeutics Revenue 2017-2028 (US$ Million)
    Figure 13. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 14. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Region (2017-2022)
    Figure 15. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Region (2023-2028)
    Figure 16. North America Recombinant Plasma Protein Therapeutics Sales YoY (2017-2028) & (K Units)
    Figure 17. North America Recombinant Plasma Protein Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 18. Europe Recombinant Plasma Protein Therapeutics Sales YoY (2017-2028) & (K Units)
    Figure 19. Europe Recombinant Plasma Protein Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales YoY (2017-2028) & (K Units)
    Figure 21. Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Latin America Recombinant Plasma Protein Therapeutics Sales YoY (2017-2028) & (K Units)
    Figure 23. Latin America Recombinant Plasma Protein Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales YoY (2017-2028) & (K Units)
    Figure 25. Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. The Recombinant Plasma Protein Therapeutics Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 27. The Top 5 and 10 Largest Manufacturers of Recombinant Plasma Protein Therapeutics in the World: Market Share by Recombinant Plasma Protein Therapeutics Revenue in 2021
    Figure 28. Global Recombinant Plasma Protein Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 29. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2017-2028)
    Figure 30. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 31. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2017-2028)
    Figure 32. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 33. North America Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2017-2028)
    Figure 34. North America Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 35. North America Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2017-2028)
    Figure 36. North America Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 37. North America Recombinant Plasma Protein Therapeutics Sales Share by Country (2017-2028)
    Figure 38. North America Recombinant Plasma Protein Therapeutics Revenue Share by Country (2017-2028)
    Figure 39. U.S. Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 40. Canada Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 41. Europe Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2017-2028)
    Figure 42. Europe Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 43. Europe Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2017-2028)
    Figure 44. Europe Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 45. Europe Recombinant Plasma Protein Therapeutics Sales Share by Country (2017-2028)
    Figure 46. Europe Recombinant Plasma Protein Therapeutics Revenue Share by Country (2017-2028)
    Figure 47. Germany Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 48. France Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 49. U.K. Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 50. Italy Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 51. Russia Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 52. Asia Pacific Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2017-2028)
    Figure 53. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2017-2028)
    Figure 55. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Recombinant Plasma Protein Therapeutics Sales Share by Region (2017-2028)
    Figure 57. Asia Pacific Recombinant Plasma Protein Therapeutics Revenue Share by Region (2017-2028)
    Figure 58. China Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 59. Japan Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 60. South Korea Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 61. India Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 62. Australia Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 63. Taiwan Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 64. Indonesia Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 65. Thailand Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 66. Malaysia Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 67. Philippines Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 68. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2017-2028)
    Figure 69. Latin America Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 70. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2017-2028)
    Figure 71. Latin America Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 72. Latin America Recombinant Plasma Protein Therapeutics Sales Share by Country (2017-2028)
    Figure 73. Latin America Recombinant Plasma Protein Therapeutics Revenue Share by Country (2017-2028)
    Figure 74. Mexico Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 75. Brazil Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 76. Argentina Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 77. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2017-2028)
    Figure 78. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2017-2028)
    Figure 80. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Share by Country (2017-2028)
    Figure 82. Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue Share by Country (2017-2028)
    Figure 83. Turkey Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 84. Saudi Arabia Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 85. U.A.E Recombinant Plasma Protein Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 86. Recombinant Plasma Protein Therapeutics Value Chain
    Figure 87. Recombinant Plasma Protein Therapeutics Production Process
    Figure 88. Channels of Distribution
    Figure 89. Distributors Profiles
    Figure 90. Bottom-up and Top-down Approaches for This Report
    Figure 91. Data Triangulation
    Figure 92. Key Executives Interviewed